Both PF-06465469 and ibrutinib significantly decreased PD-1 and LAG-3 expression (Figure 7, I and J, and Supplemental Figure 7, I–N), suggesting a potential decrease of exhaustion in CLL-CAR-T cells. The gene discussed is LAG3; the disease is B-cell chronic lymphocytic leukemia.